Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
Status:
Completed
Trial end date:
2006-09-27
Target enrollment:
Participant gender:
Summary
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent
in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.